Cargando…

Novel TNF receptor-1 inhibitors identified as potential therapeutic candidates for traumatic brain injury

BACKGROUND: Traumatic brain injury (TBI) begins with the application of mechanical force to the head or brain, which initiates systemic and cellular processes that are hallmarks of the disease. The pathological cascade of secondary injury processes, including inflammation, can exacerbate brain injur...

Descripción completa

Detalles Bibliográficos
Autores principales: Rowe, Rachel K., Harrison, Jordan L., Zhang, Hongtao, Bachstetter, Adam D., Hesson, David P., O’Hara, Bruce F., Greene, Mark I., Lifshitz, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964690/
https://www.ncbi.nlm.nih.gov/pubmed/29789012
http://dx.doi.org/10.1186/s12974-018-1200-y
_version_ 1783325227818680320
author Rowe, Rachel K.
Harrison, Jordan L.
Zhang, Hongtao
Bachstetter, Adam D.
Hesson, David P.
O’Hara, Bruce F.
Greene, Mark I.
Lifshitz, Jonathan
author_facet Rowe, Rachel K.
Harrison, Jordan L.
Zhang, Hongtao
Bachstetter, Adam D.
Hesson, David P.
O’Hara, Bruce F.
Greene, Mark I.
Lifshitz, Jonathan
author_sort Rowe, Rachel K.
collection PubMed
description BACKGROUND: Traumatic brain injury (TBI) begins with the application of mechanical force to the head or brain, which initiates systemic and cellular processes that are hallmarks of the disease. The pathological cascade of secondary injury processes, including inflammation, can exacerbate brain injury-induced morbidities and thus represents a plausible target for pharmaceutical therapies. We have pioneered research on post-traumatic sleep, identifying that injury-induced sleep lasting for 6 h in brain-injured mice coincides with increased cortical levels of inflammatory cytokines, including tumor necrosis factor (TNF). Here, we apply post-traumatic sleep as a physiological bio-indicator of inflammation. We hypothesized the efficacy of novel TNF receptor (TNF-R) inhibitors could be screened using post-traumatic sleep and that these novel compounds would improve functional recovery following diffuse TBI in the mouse. METHODS: Three inhibitors of TNF-R activation were synthesized based on the structure of previously reported TNF CIAM inhibitor F002, which lodges into a defined TNFR1 cavity at the TNF-binding interface, and screened for in vitro efficacy of TNF pathway inhibition (IκB phosphorylation). Compounds were screened for in vivo efficacy in modulating post-traumatic sleep. Compounds were then tested for efficacy in improving functional recovery and verification of cellular mechanism. RESULTS: Brain-injured mice treated with Compound 7 (C7) or SGT11 slept significantly less than those treated with vehicle, suggesting a therapeutic potential to target neuroinflammation. SGT11 restored cognitive, sensorimotor, and neurological function. C7 and SGT11 significantly decreased cortical inflammatory cytokines 3 h post-TBI. CONCLUSIONS: Using sleep as a bio-indicator of TNF-R-dependent neuroinflammation, we identified C7 and SGT11 as potential therapeutic candidates for TBI. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12974-018-1200-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5964690
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59646902018-05-24 Novel TNF receptor-1 inhibitors identified as potential therapeutic candidates for traumatic brain injury Rowe, Rachel K. Harrison, Jordan L. Zhang, Hongtao Bachstetter, Adam D. Hesson, David P. O’Hara, Bruce F. Greene, Mark I. Lifshitz, Jonathan J Neuroinflammation Research BACKGROUND: Traumatic brain injury (TBI) begins with the application of mechanical force to the head or brain, which initiates systemic and cellular processes that are hallmarks of the disease. The pathological cascade of secondary injury processes, including inflammation, can exacerbate brain injury-induced morbidities and thus represents a plausible target for pharmaceutical therapies. We have pioneered research on post-traumatic sleep, identifying that injury-induced sleep lasting for 6 h in brain-injured mice coincides with increased cortical levels of inflammatory cytokines, including tumor necrosis factor (TNF). Here, we apply post-traumatic sleep as a physiological bio-indicator of inflammation. We hypothesized the efficacy of novel TNF receptor (TNF-R) inhibitors could be screened using post-traumatic sleep and that these novel compounds would improve functional recovery following diffuse TBI in the mouse. METHODS: Three inhibitors of TNF-R activation were synthesized based on the structure of previously reported TNF CIAM inhibitor F002, which lodges into a defined TNFR1 cavity at the TNF-binding interface, and screened for in vitro efficacy of TNF pathway inhibition (IκB phosphorylation). Compounds were screened for in vivo efficacy in modulating post-traumatic sleep. Compounds were then tested for efficacy in improving functional recovery and verification of cellular mechanism. RESULTS: Brain-injured mice treated with Compound 7 (C7) or SGT11 slept significantly less than those treated with vehicle, suggesting a therapeutic potential to target neuroinflammation. SGT11 restored cognitive, sensorimotor, and neurological function. C7 and SGT11 significantly decreased cortical inflammatory cytokines 3 h post-TBI. CONCLUSIONS: Using sleep as a bio-indicator of TNF-R-dependent neuroinflammation, we identified C7 and SGT11 as potential therapeutic candidates for TBI. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12974-018-1200-y) contains supplementary material, which is available to authorized users. BioMed Central 2018-05-22 /pmc/articles/PMC5964690/ /pubmed/29789012 http://dx.doi.org/10.1186/s12974-018-1200-y Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Rowe, Rachel K.
Harrison, Jordan L.
Zhang, Hongtao
Bachstetter, Adam D.
Hesson, David P.
O’Hara, Bruce F.
Greene, Mark I.
Lifshitz, Jonathan
Novel TNF receptor-1 inhibitors identified as potential therapeutic candidates for traumatic brain injury
title Novel TNF receptor-1 inhibitors identified as potential therapeutic candidates for traumatic brain injury
title_full Novel TNF receptor-1 inhibitors identified as potential therapeutic candidates for traumatic brain injury
title_fullStr Novel TNF receptor-1 inhibitors identified as potential therapeutic candidates for traumatic brain injury
title_full_unstemmed Novel TNF receptor-1 inhibitors identified as potential therapeutic candidates for traumatic brain injury
title_short Novel TNF receptor-1 inhibitors identified as potential therapeutic candidates for traumatic brain injury
title_sort novel tnf receptor-1 inhibitors identified as potential therapeutic candidates for traumatic brain injury
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964690/
https://www.ncbi.nlm.nih.gov/pubmed/29789012
http://dx.doi.org/10.1186/s12974-018-1200-y
work_keys_str_mv AT rowerachelk noveltnfreceptor1inhibitorsidentifiedaspotentialtherapeuticcandidatesfortraumaticbraininjury
AT harrisonjordanl noveltnfreceptor1inhibitorsidentifiedaspotentialtherapeuticcandidatesfortraumaticbraininjury
AT zhanghongtao noveltnfreceptor1inhibitorsidentifiedaspotentialtherapeuticcandidatesfortraumaticbraininjury
AT bachstetteradamd noveltnfreceptor1inhibitorsidentifiedaspotentialtherapeuticcandidatesfortraumaticbraininjury
AT hessondavidp noveltnfreceptor1inhibitorsidentifiedaspotentialtherapeuticcandidatesfortraumaticbraininjury
AT oharabrucef noveltnfreceptor1inhibitorsidentifiedaspotentialtherapeuticcandidatesfortraumaticbraininjury
AT greenemarki noveltnfreceptor1inhibitorsidentifiedaspotentialtherapeuticcandidatesfortraumaticbraininjury
AT lifshitzjonathan noveltnfreceptor1inhibitorsidentifiedaspotentialtherapeuticcandidatesfortraumaticbraininjury